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ABSTRACT
It has been shown that alternative splicing is espe-
cially prevalent in brain and testis when compared
to other tissues. To test whether there is a specific
propensity of these tissues to generate splicing
variants, we used a single source of high-density
microarray data to perform both splicing factor
and exon expression profiling across 11 normal
human tissues. Paired comparisons between
tissues and an original exon-based statistical
group analysis demonstrated after extensive
RT-PCR validation that the cerebellum, testis, and
spleen had the largest proportion of differentially
expressed alternative exons. Variations at the exon
level correlated with a larger number of splicing
factors being expressed at a high level in the cere-
bellum, testis and spleen than in other tissues.
However, this splicing factor expression profile
was similar to a more global gene expression
pattern as a larger number of genes had a high
expression level in the cerebellum, testis and
spleen. In addition to providing a unique resource
on expression profiling of alternative splicing
variants and splicing factors across human
tissues, this study demonstrates that the higher
prevalence of alternative splicing in a subset of
tissues originates from the larger number of
genes, including splicing factors, being expressed
than in other tissues.
INTRODUCTION
The large functional diﬀerence between tissues results
from complex regulatory machineries that control the
tissue-speciﬁc expression of genes and yield in turn
tissue-speciﬁc proteome ensuring tissue-speciﬁc functions.
Great advances have been made using DNA microarrays
to proﬁle gene expression across tissues (1,2). However,
large-scale exon expression proﬁling is necessary to
better characterize tissue-speciﬁc gene expression regula-
tion. Indeed, the analysis of expressed sequence tags
(ESTs), splicing-sensitive microarrays, and high-
throughput sequencing data have revealed that most
human genes (upto 95% of multiexon genes) generate
transcripts having a diﬀerent exon content, by using alter-
native promoters [resulting in alternative ﬁrst exons
(AFEs)], alternative polyadenylation sites [resulting in
alternative last exons (ALEs)] and alternatively spliced
exons (ASEs) (3–9). Diﬀerent exon combinations then
impact on the protein isoforms produced. Indeed, 75%
of ASEs result in the removal of protein motifs or
domains; AFEs can result in the production of protein
isoforms with diﬀerent N-terminal sequences; and ALEs
can result in the production of C-terminal truncated
protein isoforms (10–13). Therefore, all these mechanisms
play a critical role in increasing the proteome diversity
encoded by a limited number of genes. For this reason,
we and others developed online resources designed to
provide access to reliable annotations of the transcriptome
at the exon level (14–18). These resources describe the
nature (i.e. exon content) of the transcripts produced by
each gene, as well as the potential protein isoforms
generated.
In addition to participating in cellular homeostasis,
it has been well-established that the diﬀerential exon
selection process plays a critical role during cellular
diﬀerentiating programs and development by
participating in the production of a tissue-speciﬁc
proteome (19–26). Therefore, a major challenge is now
to develop databases describing the nature of
the splicing variants expressed by each gene across
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ESTs, splicing sensitive arrays and deep sequencing have
demonstrated that some tissues, including brain and testis,
expressed more alternatively spliced transcripts than any
other tissues, suggesting that brain and testis possess an
unusually high level of alternative splicing (3,4,6–8,25–33).
However, the mechanisms behind the capability of some
tissues to generate a larger number of splicing variants
need further investigations. In particular, genome-wide
analyses of tissue-speciﬁc alternative splicing events and
tissue-speciﬁc splicing factor expression proﬁle have not
been analyzed and compared in the same dataset yet
(32,34). Indeed, regulated ASEs require the interplay of
cis- and trans-acting factors that repress or activate splice
site selection. It has been well-established that variations
of the expression level of trans-acting splicing factors play
a critical role in tissue-speciﬁc alternative splicing. These
splicing factors are members of several protein families,
including the SR, hnRNP, RBM, MBNL, CELF/CUGBP
and KH families (4,19–24,34).
In this work, we performed a genome-wide
transcriptomic analysis at the gene and at the exon levels
across 11 normal human tissues by using a unique data set
that is the Human Exon 1.0 ST Array tissue panel dataset
from Aﬀymetrix (8). We provide a list of more than 10000
exons being diﬀerentially expressed across normal human
tissues, some of them being validated by Reverse
transcription-Polymerase chain reaction (RT-PCR). In
addition, a freely available web interface (www.fast-db
.com/cgi-bin/easana/index.pl) permits, after registration,
to display the tissue dataset from any gene, which
provides information on the tissue-speciﬁc levels of alter-
native exons of the query gene. Our analysis conﬁrmed
previous observations that tissues like cerebellum and
testis express a larger set of transcripts with diﬀerent
exon content when compared to other tissues. We also
analyzed and provided the expression proﬁle of 45
splicing regulatory factors across normal tissues. By per-
forming exon and gene expression proﬁling in the same
dataset, we showed that the prevalence of alternative
splicing in the cerebellum and testis is likely to origi-
nate from a larger number of genes, including genes
coding for splicing factors that are more expressed in
these tissues.
MATERIALS AND METHODS
Aﬀymetrix exon array data analysis
The publicly available Human Exon 1.0 ST Array tissue
dataset (http://www.aﬀymetrix.com/support/technical
/sample_data/exon_array_data.aﬀx/) consists in 11
normal human triplicate tissues. The Human Exon 1.0
ST Array tissue panel dataset analysis and visualization
were made using EASANA (GenoSplice technology,
www.genosplice.com), which is based on the FAST DB
annotation (17,18). The EASANA visualization module
is a web-based interface available after registration at
www.fast-db.com/cgi-bin/easana/index.pl.
Data pre-treatment
Exon Array data were normalized by using quantile nor-
malization method. Background correction was made by
using the antigenomic probes and probe selection was
made as described previously (8). Only probes targeting
exons annotated from FAST DB transcripts were selected
in order to focus on well-annotated genes, whose mRNA
sequences are in public databases (17,18). Among these
selected probes, bad-quality probes (e.g. probes labeled
by Aﬀymetrix as ‘cross-hybridizing’) and probes with
too low intensity signal compared to antigenomic back-
ground probes with the same GC content were removed
from the analysis. Only probes with a DABG P-value
 0.05 in at least half of the arrays were considered for
statistical analysis (8).
Paired comparisons
Fifty-ﬁve paired comparisons were performed by
comparing tissues to each other. Diﬀerentially expressed
exons were identiﬁed using the splicing index strategy (8)
between triplicate experiment sets from two tissues. Only
exons from genes expressed in both compared tissues were
analyzed. To be considered as expressed, the Log2 gene
signal intensity had to be  6.0 and the DABG P-value
had to be  0.05 for at least half of the gene probes. We
performed a paired Student’s t-test to compare the
gene-normalized intensity (corresponding to the probe
expression level relative to the gene expression level) of
each probe in tissue paired comparisons. Therefore, all
the probes from an exon had to change similarly to
predict the exon as being diﬀerentially expressed. Exons
were considered signiﬁcantly diﬀerentially regulated when
the splicing index fold change was  1.5 and the splicing
index P-value was  0.05.
Tissue group comparisons
An exon-based statistical group analysis was performed
by also using the splicing index strategy. First, the
‘gene-normalized exon intensity’ value in each tissue was
calculated for all the exons of all the genes signiﬁcantly
expressed in this tissue. To each exon corresponded three
values as the arrays data were generated in triplicate.
Second, the average of the ‘gene-normalized exon inten-
sity’ values was calculated for each exon and each tissue
(Supplementary Figure S1). Therefore, several numbers
(each of them corresponding to the average of the
gene-normalized exon intensity values in one tissue) were
attributed to each exon. These numbers were then sorted
by ascending order for each exon to generate tissue
groups. Third, the averages of the gene-normalized exon
intensity values were then replaced by the corresponding
values obtained in the three experiments in order to
perform a statistical analysis on the ascending order.
Thanks to this strategy, an unpaired Student’s t-test was
performed for each possible group, each group being
between three values (when the group contained only
one tissue) and 30 values (when the group contained 10
tissues). Finally, the cut point deﬁning two groups of
values being statistically signiﬁcantly diﬀerent was
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possible comparison. Groups were considered signiﬁcantly
diﬀerent when the p-value was  0.05 and the fold change
was  1.5. Constituted groups were then separated in indi-
vidual tissues. A similar method was used for gene
expression-level analysis using the ‘gene signal’ that corre-
sponded to the average of all the selected gene probes.
Non-supervised hierarchical clustering (Mev4.0 software
from TIGR) using Euclidean distance with complete
linkage method was carried out to cluster gene-normalized
intensity of diﬀerentially regulated exons of genes
expressed in at least six tissues.
Splicing and transcription factor gene expression
across tissues
The gene signals from 45 splicing factors identiﬁed in the
literature and 1250 transcription factors identiﬁed in the
DBD database (http://dbd.mrc-lmb.cam.ac.uk) were
retrieved after pre-treatment of the data. Intensity values
were displayed with MeV4.0. In addition, the average of
the gene signal in the 11 tissues was calculated for each
splicing or transcription factor. The distance from the
gene signal in a given tissue to the corresponding
average in the 11 tissues was calculated. The number of
splicing or transcription factors with a tissue-speciﬁc gene
expression level either above or below (with a 1.2 factor)
the gene expression average value in the 11 was calculated.
Global gene expression level
Probe expression analysis was performed with the
Expression Console software from Aﬀymetrix (8) to
count the number of probesets and genes expressed
above DABG across the 11 tissues.
Validation by RT-PCR
One microgram of total RNAs from human breast, cere-
bellum, heart, liver, muscle, spleen or testis (BioChain)
was reverse-transcribed using random primers and the
Superscript II reverse transcriptase (Invitrogen).
cDNAs were diluted 400 times and 5ml of the diluted
cDNAs were used for PCR ampliﬁcation using GoTaq
DNA polymerase (Promega). Primer sequences are
provided in Supplementary Table S1.
RESULTS
Identiﬁcation of diﬀerentially expressed exons across
11 normal human tissues
To identify diﬀerentially expressed exons across normal
human tissues, we analyzed the publicly available
dataset from Aﬀymetrix (www.aﬀymetrix.com) in which
RNAs from 11 normal human tissues were hybridized on
GeneChip Human Exon 1.0 ST Arrays. Exon arrays
contain multiple probes per exon, allowing to analyze
gene expression at both transcript and exon levels (8).
Using the EASANA analysis system from GenoSplice
technology (www.genosplice.com), 13843 human genes
were analyzed after the selection of ‘good-quality’
probes targeting well-annotated exons of genes with
known mRNAs (Figure 1A). Fifty-ﬁve paired compari-
sons of the tissues with each others were performed in
order to identify the largest number of diﬀerentially
expressed exons across tissues. For each paired compari-
son of tissues, only genes signiﬁcantly expressed in both
tissues were considered for analysis at the exon level. A
Student’s t-test was performed to test the diﬀerence
between ‘splicing index values’ as previously reported
(8). Diﬀerences between ‘splicing index values’ were con-
sidered statistically signiﬁcant for fold-changes  1.5 and
P-values  0.05.
Between 88 and 2607 diﬀerentially expressed exons
were identiﬁed depending on the paired comparison
(Figure 1B). After, considering individual tissues,
between 1413 (pancreas) and 6827 (cerebellum)
diﬀerentially expressed exons were identiﬁed by taking
into account that some exons were simultaneously found
in several paired comparisons (Figure 1C). Across the 11
tissues, 11196 diﬀerent exons were diﬀerentially expressed,
which corresponded to 3264 diﬀerent genes. The cerebel-
lum and testis, followed by the spleen, were the tissues
with the largest number of exons being diﬀerentially
expressed (Figure 1B and C). The list of the diﬀerentially
expressed exons obtained for each paired comparison is
given in Supplementary Table S2, which provides a unique
resource of diﬀerentially expressed alternative exons.
While paired comparisons of tissues identiﬁed exons
that were diﬀerentially expressed between two tissues,
they did not allow to determine which tissue or group of
tissues speciﬁcally expressed a given splicing variant. For
that purpose, we compared the exon content of the
products of each human gene by considering all the
tissues where the gene was expressed in order to identify
alternative exons speciﬁc to tissues. An exon-based statis-
tical group analysis was performed using the
‘gene-normalized exon intensity’ value that corresponded
to the exon expression level relative to the gene expression
level as described in ‘Materials and methods’ section and
in Supplementary Figure S1. Using this strategy, 1073
unique exons corresponding to 653 unique genes were
associated with individual tissues or a group of tissues
(including no more than ﬁve tissues within a group).
Exons found in a group of tissues were then associated
with each individual tissue of the group. Between 33 and
349 diﬀerentially expressed exons were associated with
each tissue as indicated on Figure 2A. The list of the
genes containing exons that were diﬀerentially expressed
in speciﬁc tissues is given in Supplementary Table S3,
which provides a unique resource of exons being
diﬀerentially expressed in a tissue-speciﬁc manner.
Three major groups of tissues were revealed by this
analysis according to the diﬀerential expression of exons.
Cerebellum, testis and spleen had the largest amount and
proportion of diﬀerentially expressed exons (i.e. 24, 16 and
14%, respectively) when compared to the other tissues
(Figure 2A and B). A second group of tissues was
composed of muscle, heart, liver and thyroid that con-
tained between 7 and 10% of the exons being diﬀerentially
expressed across tissues. A third group was composed
of the prostate, pancreas, breast and kidney that
Nucleic Acids Research,2010, Vol.38, No. 9 2827contained,<4% of the exons being diﬀerentially expressed
across tissues.
A non-supervised hierarchical clustering analysis using
Mev4.0 software (TIGR, http://www.tm4.org/) based on
‘gene-normalized exon intensity’ values supported this
observation. It revealed that each tissue contained alter-
native exons that were preferentially either included or
excluded, as there were exons with both positive and
negative ‘gene-normalized exon intensity’ values in each
tissue (Figure 2C and D). Therefore, both paired compar-
isons of tissues and exon-based statistical group analyses
revealed that cerebellum, testis and spleen possess a larger
proportion of diﬀerentially expressed exons than other
tissues.
Figure 1. Identiﬁcation of diﬀerentially expressed exons by paired comparisons. (A) Workﬂow. The exon and gene expression proﬁling across 11
normal tissues was performed using the same dataset from Aﬀymetrix. Stringent criteria were used to select probes from genes expressed in at least
two tissues in order to compare the exon content of well-expressed transcripts produced from annotated genes. Among 18008 human genes
annotated in FAST DB based on publicly available mRNA sequences, 13843 genes were deﬁned by >60% of high-quality probes. (B) Number
of exons being diﬀerentially expressed when comparing two tissues as indicated. Fifty-ﬁve paired comparisons were performed by comparing
each tissue to each other. Comparisons between two tissues were performed by considering only genes that were well expressed in both
tissues. (C) Number of diﬀerentially expressed exons identiﬁed for each tissue. Each tissue contained a number of unique diﬀerentially expressed
exons.
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validation by RT-PCR
To test by RT-PCR some of the events identiﬁed above,
we selected exons predicted in the group comparison that
were also predicted in several paired comparisons. Within
them, we next selected exons with splicing index
fold-changes within the range of all the splicing index
fold-changes predicting alternative exons (Supplementary
Figure 2. Identiﬁcation of diﬀerentially expressed exons by group comparison. (A) Number of diﬀerentially expressed exons and number of corre-
sponding genes identiﬁed by a group comparison. Tissue ranking was done depending on the number of diﬀerentially expressed exons associated with
each tissue. (B) Proportion of diﬀerentially expressed exons identiﬁed for each tissue. The number of diﬀerentially expressed exons associated with
each tissue was divided by the total number of diﬀerentially expressed exons identiﬁed by a group comparison. (C) Non-supervised hierarchical
clustering of gene-normalized exon intensities. Diﬀerentially regulated exons across 11 tissues were hierarchically clustered based on their
gene-normalized exon intensity. Color scale representing gene-normalized exon intensity is shown below the clustergram. (D) Proportion of
‘splicing index’ fold-changes that were up or down in the tissue group comparison. ‘Splicing index’ values corresponding to the exons identiﬁed
in the statistical group comparison for each individual tissue were either up (preferentially included) or down (preferentially excluded).
Nucleic Acids Research,2010, Vol.38, No. 9 2829Figure 3. Annotation and validation of ASEs. (A) Classiﬁcation of alternative exons. Alternative exons can be classiﬁed either as AFEs, ALEs or
ASEs. ASEs can be extended or shortened through the use of alternative 50- and 30-splice sites and introns can be spliced out or retained. (B) CLTB
gene analysis. Genomic structure of the CLTB gene (upper panel). According to FAST DB exon numeration and annotation, the human CLTB gene
contains 6 exons and one ASE (indicated by red lines below exon 5). Graphical representation of the exon array probes corresponding to the CLTB
gene in the cerebellum compared to the other tissues (lower panel). Each Aﬀymetrix probe corresponding to the CLTB gene is represented by a bar
above the numbered grey exons of the gene. The height of each bar is proportional to the mean intensity of the corresponding probe, as calculated
from three independent experiments for a given tissue (in this case, the cerebellum). In addition, the color of each bar is proportional to the
diﬀerences in probe intensities between samples (in this case, cerebellum compared to the mean intensity calculated for the 10 other tissues): a red bar
means that the intensity of the corresponding probe was greater in the cerebellum; black corresponds to probes with no intensity variation; and a
green bar indicates that the intensity of the corresponding probe was lower in the cerebellum. The bright red bars corresponding to exon 5 indicate
that exon 5 may be more included in the cerebellum than in other tissues. Screenshot is from EASANA.( C) RT-PCR analysis. RT-PCR analyses
for several ASEs predicted to be diﬀerentially expressed between tissues.
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classify the diﬀerentially expressed exons into AFEs
resulting from alternative usage of promoters, ALE
resulting from alternative usage of polyadenylation sites,
or ASE (Figure 3A). In addition, ASEs can be extended or
shortened by the usage of alternative 50- and 30-splice sites,
and introns can be spliced out or retained (Figure 3A). In
an attempt to classify the 1073 diﬀerentially expressed
exons across tissues identiﬁed above (Figure 2A), a
manual inspection was performed after uploading the
Exon Array data into the EASANA visualization
module, which is based on the FAST DB annotations.
FAST DB is a database gathering all the known and
well-annotated human alternative transcripts (17,18). By
computational comparison of publicly available mRNA
sequences with genomic sequences, alternative exons
have been annotated in FAST DB as AFEs, ASEs, or
ALEs (17,18).
To illustrate the annotation process, the CLTB gene
was provided as an example on Figure 3B. A brain-speciﬁc
CLTB splicing variant containing a supplementary exon
(exon 5 on Figure 3B) has been cloned and results in the
production of a protein isoform containing a supplemen-
tary conserved region of 22 residues near the amino
terminus (35). The alternative splicing of exon 5 is
indicated by a broken red line below exon 5 (upper
panel, Figure 3B). To manually inspect the Exon Array
data, each Aﬀymetrix probe corresponding to the CLTB
gene is computationally represented by a bar above the
numerated gray exons (lower panel, Figure 3B). The
color of each bar indicates the variation of the probe
intensity across tissues (in that case, the probe intensity
in the cerebellum compared to the mean probe intensity
obtained in the 10 other tissues). Bright red bars corre-
sponding to exon 5 probes (lower panel, Figure 3B) sug-
gested that CLTB exon 5 was more frequently included in
the cerebellum than in the other tissues. This prediction
was validated by RT-PCR as exon 5 was speciﬁcally
included in the cerebellum (CLTB, Figure 3C). Likewise,
several cassette exons were identiﬁed and validated, as
illustrated for the ABLM1, PBRM1, SIPA1L1,
MICAL2 and VPS39 genes (Figure 3C). Cases of 50-
and 30-alternative spliced sites and intron retentions were
also identiﬁed and validated, as illustrated for the SXN13,
ARL6IP2, PICALM and REPS1 genes (Figure 3C).
In addition to these alternative splicing events, we
identiﬁed and validated several cases of alternative
polyadenylation sites, as illustrated for the ATP2A2 gene
(upper panel, Figure 4A). The transcripts produced by the
ATP2A2 gene can end either in intron 20 or in exon 21, as
indicated by the ‘pA’ symbol above exons 20 and 21. Exon
array data suggested that the ratio of the transcripts
ending in intron 20 or exon 21 varied when comparing
heart (or muscle, not shown) to the other tissues (lower
panel, Figure 4A). This case was validated by RT-PCR
analysis (ATPA2, Figure 4B), as well as several other cases
of alternative polyadenylation sites, as illustrated on
Figure 4B for the MARCH6, VPS13C and MICAL2
genes.
Another mechanism leading to variation in mRNA
exon content involves alternative promoters (Figure 3A).
This was illustrated by the IDE gene that contains an
internal promoter indicated by a red arrow above exon
18 (upper panel, Figure 4C). Remarkably, only the inten-
sity of the probes corresponding to exon 18 and down-
stream exons varied when comparing testis to the other
tissues (lower panel, Figure 4C). RT-PCR analysis
demonstrated that testis more strongly expressed the
forms starting in exon 18 than other tissues (IDE,
Figure 4D). Other diﬀerentially expressed alternative pro-
moters were identiﬁed and validated, as illustrated for the
SPTBN1, ABLIM1 and CLASP2 genes (Figure 4D).
Among the 1073 events identiﬁed above (Figure 2A),
26, 4 and 5% corresponded to cassette exons, intron reten-
tions and 50-o r3 0-spliced sites, respectively (Figure 4G),
and 15 and 12% corresponded to AFE and ALEs, respec-
tively (Figure 4G). This repartition is in agreement with
the proportion of these diﬀerent types of alternative exons
in databases (3–9,14–18,36).
We also identiﬁed a large set of predicted diﬀerentially
expressed exons that were not annotated as alternative
exons in FAST DB (Figure 4G, unclassiﬁed events). For
example, ANK3 exon 16 was predicted to be diﬀerentially
expressed when comparing heart to the other tissues
(Figure 4E). RT-PCR analysis demonstrated that ANK3
exon 16 was more frequently skipped in heart than in the
other tissues (Figure 4F). The list of events and their anno-
tation is given in Supplementary Data for each tissue
(Supplementary Table S3), which provides a resource for
alternative exons not being yet annotated in databases. It
is also possible to use the EASANA visualization module
(Supplementary Figure S2) to retrieve information on the
tissue-speciﬁc levels of annotated or new alternative
exons of queried genes (www.fast-db.com/cgi-bin/easana
/index.pl).
Expression proﬁle of splicing factors across tissues
The classiﬁcation of the diﬀerentially expressed exons
across the 11 tissues by alternative event categories, that
is, ASEs, AFEs and ALEs, revealed a similar rank as that
observed on Figure 2B. In particular, the cerebellum, testis
and spleen were enriched in ASEs being diﬀerentially
expressed when compared to the other tissues (ASE,
Figure 5A).
Because ASEs are controlled by splicing factors, we next
investigated the expression proﬁle of splicing factors
across tissues in the same dataset to be able to compare
genome-wide alternative splicing events and splicing
factor expression proﬁle. In the literature, we selected 45
well-characterized splicing regulatory factors that have
been shown to participate in the selection of ASE. These
include members of the SR, hnRNP, RBM, MBNL,
CELF and KH families (4,19–24,34). All these factors
are known to recognize and bind to RNA regulatory
sequences located in introns and/or exons and to control
the use of splicing sites selected by the spliceosome. The
normalized gene expression values (gene signals) of the
45 splicing regulatory factors across the 11 tissues were
retrieved. Intensity values were then displayed with
MeV4.0. This analysis revealed that, ﬁrst, each tissue
was characterized by a speciﬁc splicing factor expression
Nucleic Acids Research,2010, Vol.38, No. 9 2831Figure 4. Annotation and validation of alternative ﬁrst and last exons. (A) ATP2A2 gene analysis. Genomic structure of the ATP2A2 gene (upper
panel). According to FAST DB exon numeration and annotation, the human ATP2A2 gene contains 21 exons and two potential last exons, as
indicated by a pA symbol above exons 20 and 21. Graphical representation of the exon array probes corresponding to the ATP2A2 gene in the heart
compared to the other tissues (lower panel). Each Aﬀymetrix probe corresponding to the ATP2A2 gene is represented by a bar above the numbered
grey exons of the gene. The bright green bars corresponding to 30-end extended exon 20 and the red bars corresponding to exon 21 indicated that
exons 20 and 21 were diﬀerentially used between heart and other tissues. Screenshot is from EASANA.( B) RT-PCR analysis of ALEs. RT-PCR
analyses for several ALEs predicted to be diﬀerentially expressed between tissues. (C) IDE gene analysis. Genomic structure of the IDE gene
(upper panel). According to FAST DB exon numeration and annotation, the human IDE gene contains 34 exons and three potential ﬁrst exons,
as indicated by a red arrow above exons 1, 2 and 18. Graphical representation of the exon array probes corresponding to the IDE gene in the testis
compared to the other tissues (lower panel). Each Aﬀymetrix probe corresponding to the IDE gene is represented by a bar above the numbered grey
(continued)
2832 Nucleic Acids Research, 2010,Vol.38, No. 9proﬁle (columns, Figure 5B). Second, each splicing factor
presented a speciﬁc expression proﬁle across tissues (lines,
Figure 5B). Many features of this analysis have been
previously reported, as it will be underlined in the
‘Discussion’ section.
This analysis also suggested that cerebellum, testis and
spleen expressed the largest number of splicing factors at a
relatively high level. To test this hypothesis, we quantiﬁed,
for each tissue, the number of splicing factors having a
gene expression value above or below the corresponding
mean gene expression value calculated for the 11 tissues
(Supplementary Table S4). As shown on Figure 5C and D,
a larger proportion of splicing factors was highly
expressed (i.e. gene expression value above the mean) in
the cerebellum, testis and spleen than in the other tissues,
and a smaller proportion of splicing factors was poorly
expressed (i.e. gene expression value below the mean)
in the cerebellum, testis and spleen than in the other tis-
sues. These data indicated that tissues with the largest
number of diﬀerentially expressed ASEs (Figure 5A)
also had the largest number of highly expressed splicing
factors (Figure 5B–D). The expression pattern of splicing
factors can be retrieved either in Supplementary Table S4
and Figure S4 or by using the EASANA visualization
module as described in Supplementary Figure S5.
Global gene expression level
To test whether there was a propensity of cerebellum,
testis and spleen to generate transcripts with a diﬀerent
exon content from that of other tissues (Figure 5A), we
investigated whether a high expression level of splicing
factors was a speciﬁc feature of these tissues. First,
similar results were obtained by performing transcription
factor gene expression proﬁling, as a larger proportion of
transcription factors were more expressed in the cerebel-
lum, testis and spleen than in the other tissues and a
smaller proportion of transcription factors were less
expressed in the cerebellum, testis and spleen than in the
other tissues, as observed for splicing factors (comparing
Figures 5C and 6A). Second, we observed that a larger
proportion of probesets were above the DABG in the cer-
ebellum, testis and spleen than in the other tissues
(Figure 6B). Third, there were almost twice more genes
expressed in the cerebellum, testis, and spleen than in
the other tissues (Figure 6C). Finally, a statistical group
analysis based on gene expression level (gene signal)
revealed that the tissues expressing a larger proportion
of diﬀerentially expressed genes were those expressing a
larger proportion of diﬀerentially expressed exons
(comparing Figures 2B and 6D). Therefore, these
analyses revealed that the larger number of splicing
factors being highly expressed in the cerebellum, testis
and spleen (Figure 5C and D) is likely to be part of a
more global proﬁle of gene expression (Figure 6). This
was strengthened by the observation of a similar ranking
by analyzing ASEs, AFE and ALEs (Figure 5A).
Altogether, the apparent propensity of cerebellum, testis
and spleen to express more alternative transcripts than
other tissues is likely to originate from their ability to
express more genes.
This conclusion was further supported by the analysis
of the splicing pattern of genes expressed in all analyzed
tissues. As shown on Figure 6E and F, all tissues con-
tained a similar proportion of genes producing alternative
exons by using only the set of ubiquitous genes in contrast
to what we observed by using all genes (Figures 1 and 2).
However, each tissue expressesed diﬀerent splicing
isoforms produced from the ubiquitous genes, as
illustrated on Supplementary Figure S9. This was
expected as the diﬀerent tissues did not express the same
set of splicing factors (Figure 5).
Biological impact of tissue-speciﬁc exons
To test whether the genes bearing diﬀerentially expressed
exons across tissues were involved in speciﬁc biological
processes, we performed a functional analysis using the
PANTHER software (www.pantherdb.org). The 653
analyzed genes containing diﬀerentially expressed exons
across tissues (Figure 2A) were enriched for Gene
Ontology functional categories, including ‘cell structure
and motility’, ‘intracellular protein traﬃc’, ‘protein target-
ing and localization’ and ‘protein metabolism and modi-
ﬁcation’ (Figure 7A). Therefore, the functions of genes
products that control the fate and post-translational mod-
iﬁcations of proteins may be particularly aﬀected by dif-
ferential exon selection in a tissue-speciﬁc manner.
Remarkably, by comparing the genes having a diﬀerential
expression across tissues (Figure 6D), we observed that
‘cell structure and motility’ and’protein targeting and
localization’ were processes enriched in the ‘splicing’ list
compared to the ‘transcription’ list. Noteworthy, many
alternative splicing events aﬀect protein domains that
control the intracellular localization of proteins by
deletion/insertion of exons coding for subcellular localiza-
tion signals (10). Therefore, tissue-speciﬁc alternative
splicing events may impact the proteome, ﬁrst by aﬀecting
protein domains and second by aﬀecting gene products
involved in the control of protein modiﬁcations and fate.
Furthermore, we observed a large set of transcriptional
regulators bearing tissue-speciﬁc diﬀerentially expressed
Figure 4. Continued
exons of the gene. The bright red bars corresponding to exon 18 and downstream exons indicated that the transcripts starting with exon 18 were
more expressed in the testis than in other tissues. Screenshot is from EASANA.( D) RT-PCR analysis of AFEs. RT-PCR analyses for several AFEs
predicted to be diﬀerentially expressed across tissues. (E) ANK3 gene analysis. Genomic structure of the ANK3 gene and graphical representation of
the exon array probes corresponding to the ANK3 gene in the heart compared to the other tissues (upper and lower panels). Each Aﬀymetrix probe
corresponding to the ANK3 gene is represented by a bar above the numbered grey exons of the gene. The black bars corresponding to exon 16
compared to the red bars corresponding to the other exons indicate that exon 16 may be skipped in the heart. Screenshot is from EASANA.( F)
RT-PCR analysis for the ANK3 gene. The RT-PCR analyses for the ANK3 gene demonstrated that ANK3 exon 16 was more frequently skipped in
the heart than in other tissues. (G) Classiﬁcation of the diﬀerentially expressed exons between tissues. Sixty-one percent of the diﬀerentially expressed
exons across tissues were already annotated in FAST DB as ASEs, AFEs or ALE.
Nucleic Acids Research,2010, Vol.38, No. 9 2833exons (Supplementary Table 5), as previously reported
(13). This was illustrated with the PBRM1 and TCF12
genes (Figure 7B). Therefore, the transcriptome diver-
sity at the exon level originates from tissue-speciﬁc
gene expression level and in turn impacts on gene
transcriptional control. In conclusion, tissues expressing
a larger set of genes, including splicing factors, express
diﬀerent splicing variants when compared to other
tissues (Figure 7C). Divergences with other tissues
increase consequently, as protein isoforms translated
from these splicing variants diﬀerentially impact protein
fate, as well as gene expression regulation (Figure 7C).
DISCUSSION
In this study, we developed bioinformatics tools to proﬁle
gene and exon expression across 11 normal human tissues.
In particular, we provided a list of more than 10000 exons
being diﬀerentially expressed across normal human tissues
(Supplementary Tables S2 and 3). In addition, a freely
available web interface (www.fast-db.com/cgi-bin
/easana/index.pl) permits after registration to display
tissue dataset from any gene, which provides access to
splicing variant expression proﬁle across normal tissues
of query genes (see Supplementary Figures S2 and 9 for
details regarding the use of the web interface). We also
provided the expression proﬁle of 45 splicing regulatory
factors across normal tissues (Figure 5, Supplementary
Table S4 and Figure S4), which can be extended to any
queried gene thanks to the freely available web interface,
as described in Supplementary Figure S5.
It has been well-established that some tissues, including
brain and testis, express a larger set of splicing variants
than other tissues (3–9,21–26,36). In this study, we
demonstrated for the ﬁrst time that spleen is also a
Figure 5. Proﬁle of splicing factors gene expression across 11 tissues. (A) Tissue ranking of classiﬁed and diﬀerentially expressed exons across tissues.
A similar tissue ranking was obtained for ASEs, AFEs and ALE that were diﬀerentially expressed across tissues. (B) HeatMap of 45 splicing factor
gene intensity. The color scale representing gene normalized intensity is shown below the HeatMap. (C) Proportion of splicing factors being up- or
down-expressed in each tissue compared to their average expression level in the 11 tissues. The mean of the gene signal in the 11 tissues was
calculated for each splicing factor. The distance between the gene signal in a given tissue and the corresponding mean in the 11 tissues was calculated.
The number of splicing factors with a gene expression level above or below the gene expression average in the 11 tissues was calculated. (D) Number
of splicing factors being up- or down-expressed in each tissue. The number of splicing factors being less expressed in a given tissue was subtracted
from the number of splicing factors being more expressed in the same tissue.
2834 Nucleic Acids Research, 2010,Vol.38, No. 9tissue expressing a high proportion of alternative tran-
scripts (Figure 2). Remarkably, several recent reports
have indicated that alternative splicing plays a critical
role in the activation of lymphocytes during the immune
response that occurs in part in spleen (37). A critical role
for the HNRNPL splicing factor, which is more expressed
in spleen than in other tissues (Supplementary Figure S3)
as already reported, has been shown in this process
(38–40).
To better understand the prevalence of alternative
splicing in a set of tissues, we analyzed the expression
level of splicing factors in the same dataset.
Figure 6. Proﬁle of gene expression across 11 tissues. (A) Number of transcription factors being up- or down-expressed in each tissue compared to
their average expression level in the 11 tissues. The mean of the gene signal in the 11 tissues was calculated for each transcription factor. The distance
between the gene signal in a given tissue and the corresponding mean in the 11 tissues was calculated. The number of transcription factors with a
gene expression level above or below the gene expression average in the 11 tissues was calculated. (B) Percentage of selected probesets expressed
above DABG in each tissue. (C) Number of genes expressed above DABG in each tissue. (D) Statistical group analysis of gene expression levels. The
tissue ranking using gene expression level (gene signal) values in parallel to those of alternative exons (compared with Figures 2B); that is, the same
types of samples with the largest number of diﬀerentially expressed exon (spleen, cerebellum and testes, see Figure 2B) were among those with the
most diﬀerentially expressed genes. (E) Percentage in each tissue of genes that were signiﬁcantly expressed in 11 tissues and that contained
diﬀerentially expressed exons in paired comparisons. The proportion of genes with diﬀerentially expressed exons in each tissue was calculated
among 524 genes (corresponding to 100%) that were signiﬁcantly expressed in the 11 tissues and that were predicted to contain diﬀerentially
expressed alternative exons in all paired comparisons. (F) Percentage in each tissue of genes that were signiﬁcantly expressed in 11 tissues and
that contained diﬀerentially expressed exons in group comparisons. The proportion of genes with diﬀerentially expressed exons in each tissue was
calculated among 196 genes (corresponding to 100%) that were signiﬁcantly expressed in the 11 tissues and that were predicted to contain
diﬀerentially expressed alternative exons in all group comparisons.
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splicing events and tissue-speciﬁc splicing factor expres-
sion proﬁle had not been performed in the same dataset
yet (32,34). Because tissue ranking, which is based either
on the number of diﬀerentially expressed exons or on the
number of diﬀerentially expressed genes, is likely to
depend on the compared tissues, an important improve-
ment of our analysis was to draw conclusions that derived
from the same dataset to survey exon and gene proﬁling.
Thanks to this strategy, we demonstrated for the ﬁrst time
that tissues expressing the largest proportion of splicing
variants (Figures 1 and 2) were tissues that expressed the
largest number of splicing factors at a high level
(Figure 5). High level of a larger number of splicing
factors is expected to improve the chance of exons to be
diﬀerentially selected: two tissues expressing the same set
of splicing factors are more likely to express the same
splicing variants compared to a tissue that would express
a diﬀerent set of splicing factors (3,4,19–24). In addition,
as each tissue was characterized by a speciﬁc splicing
factor expression proﬁle (Figure 5B) and as a larger
number of splicing factors being expressed in a tissue
increases the number of possible combinations for the
ratio between splicing factor levels, the possibility of alter-
native splicing regulation in this tissue may in turn
increase, given the combinatorial mode of splicing regula-
tion. A limit to this analysis is that DNA microarray data
measure mRNA expression levels. However, among the
splicing factors that were highly expressed in the set of
analyzed tissues (Figure 5B, Supplementary Table S4
and Figure S3), several cases have been well documented
at both RNA and protein levels. For examples, NOVA1
and PTB2, but not PTB1, are highly expressed at the
mRNA and protein levels in the cerebellum (4,23,24,26);
CUGBP2 (ETR-3) protein has been shown to be more
expressed in brain and spleen than other tissues (4,22);
MBNL3 protein has been shown to be expressed in
testis, spleen and liver, but not in brain, muscle and
heart (21); a restricted and high expression level of
A2BP1 (FOX1) protein in cerebellum, muscle and heart
has been reported (26). Although some mRNAs encoding
splicing factors may not be translated, there is probably a
strong relationship between the large number of splicing
factors being more expressed in the cerebellum, testis and
spleen, and the capability of these tissues to express more
splicing variants than other tissues.
The large number of splicing factors being express in
cerebellum, testis and spleen (Figure 5) is part of a more
global gene expression proﬁle because these tissues express
a larger number of genes, including transcription factors,
at higher levels (Figure 6). This large number of expressed
genes in the cerebellum has already been reported and it
was estimated that >50% of the mouse genome would be
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Figure 7. Functional consequences of diﬀerential exon selection. (A) Biological process. Number of genes presenting diﬀerentially regulated exons
across tissues and associated with speciﬁc biological processes as deﬁned by PANTHER (www.pantherdb.org). Biological process analysis was
performed using Bonferroni correction. Statistical signiﬁcance calculated by comparing splicing-regulated genes to the genome or splicing-regulated
genes to transcriptional-regulated genes. (B) RT-PCR analysis. The RT-PCR analyses for the PBRM1 and TCF12 transcriptional factors
demonstrated that diﬀerent spliced isoforms were diﬀerentially expressed across analyzed tissues. (C) Successive layers of regulation drive an
increasing divergence between tissues. Key transcriptional regulators determine the nature and the number of genes being expressed during cell
specialization. Tissues expressing a larger number of genes express a larger number of splicing factors that in turn impact the exon content of the
gene products (1). Transcriptional regulators may also aﬀect transcript exon content (1’). As a consequence, the transcriptome diﬀers in terms of both
transcript expression level and transcript exon content, resulting in a more diversiﬁed proteome (2). Outcomes of diﬀerentially expressed exons
impinge on a third layer of regulation [(3), the ‘functional proteome’] as there was an enrichment of splicing-regulated genes involved in ‘intracellular
protein traﬃc’ and ‘protein metabolism and modiﬁcation’. This process may be maintained by impacting on transcriptional regulators (4).
2836 Nucleic Acids Research, 2010,Vol.38, No. 9(1,25). This propensity of a set of tissues to express a larger
number of genes is likely to have two major impacts in
terms of alternative splicing. First, splicing factors are
among the genes that are more expressed in these
tissues. Second, increasing the number of genes that are
expressed in a given tissue increases the probability of
generating splicing variants. Therefore, it can be
concluded that higher levels of alternative splicing events
in a set of human tissues originate from their ability to
express a larger set of genes. These tissues are likely to
express highly speciﬁc splicing factors, as recently shown
in the nervous system (41), in the same way as they express
other tissue-restricted genes like transcriptional factors. A
third mechanism by which tissue-speciﬁc transcriptional
programs may impact on splicing is based on the func-
tional coupling between transcription and splicing.
Although, we observed no correlation between gene
expression regulation or gene expression level and
splicing (Supplementary Figures S6 and 7) as previously
reported (42), a rather qualitative than quantitative
change in gene transcriptional activity may impact gene
product splicing owing to alternative promoter usage and/
or chromatin marks. Indeed, it has been shown that an
alternative promoter switch can impact on the exon
content of the gene products (43) and increasing evidences
indicate a link between chromatin marks and splicing (44).
Therefore, tissue-speciﬁc transcriptional programs may
impact on the transcriptome at the exon level, either
directly or indirectly through splicing factor expression
level. In both cases, the apparent propensity of tissues
like cerebellum, testis and spleen to generate more
splicing variants is likely to be a consequence of a global
gene expression pattern. This conclusion is supported by
our observation that all three types of alternative exons
controlled by alternative promoters, splicing and
polyadenylation, respectively, were more prominent in
the cerebellum, testis and spleen (Figure 5A).
Our analysis supports a simple model where the diver-
gence between tissues is expanding through successive
layers of regulation starting from the number (and
obviously the identity) of expressed genes. The ﬁrst layer
of regulation that controls the number of genes expressed
in a tissue impinges on a second layer of regulation con-
trolling splicing variants expression. Indeed, more genes
expressed in a tissue will increase the ability to generate
splicing variants that results in proteome diversity
(Figure 7C). Outcomes of diﬀerentially expressed exons
impinge on a third layer of regulation (the ‘functional
proteome’) as there was an enrichment in
splicing-regulated genes involved in ‘intracellular protein
traﬃc’ and ‘protein metabolism and modiﬁcation’
(Figure 7A). This process may be maintained by impacting
on transcriptional regulators (Figure 7B and
Supplementary Table S5), whose functions are known to
be regulated by alternative splicing (13). Moreover, gene
expression level and alternative splicing may act comple-
mentary because some biological processes were
preferentially aﬀected by alternative splicing
(Figure 7A), as already reported in mouse (42).
Finally, the ability of some tissues to express more genes
correlated with a larger number of transcription factors
being expressed (Figure 6) and the number of diﬀerentially
expressed exons/genes in tissues may reﬂect the relative
abundance of cell types in these tissues. Indeed, the
tissues (cerebellum, testis and spleen) that express the
largest set of genes and splicing variants have a large
diversity of cell types. Therefore, the larger numbers of
genes and splicing variants being expressed in these
tissues could represent the cellular heterogeneity of these
tissues: if each cell type expresses a speciﬁc splicing
variant, cellular heterogeneity will increase the number
of splicing variants when compared to a homogenous
cell population. Accordingly, a recent study has revealed
a large number of alternative splicing variations by
comparing diﬀerent brain regions (45). Cell specialization
is a key driving force in organism complexity and recent
evidences have indicated that alternative splicing is more
frequent in organisms with increased cellular and func-
tional specialization (46). Our data support the notion
that exonic regulations play a role in cell specialization
of complex tissues in addition to the regulation of gene
expression levels.
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